Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01864538 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
A Phase 2 study, sponsored by ImmunoGenesis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01864538 is a Phase 2 study that was terminated before completion, run by ImmunoGenesis. The registered enrollment target is 11 participants.
The verdict
NCT01864538, a Phase 2 study, was terminated before completion, sponsored by ImmunoGenesis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.
Interventions
- DRUG TH-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01864538
The ClinicalTrials.gov registry entry for NCT01864538 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGenesis, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TH-302 is the first listed.
NCT01864538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01864538 about?
NCT01864538 is a clinical study titled "A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma". The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.
What is the current status of trial NCT01864538?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2013-05. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01864538?
The interventions under investigation include: TH-302 (DRUG).
Who is sponsoring clinical trial NCT01864538?
This trial is sponsored by ImmunoGenesis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.